PHARMACY

FDA points finger at several ADHD drug makers, alleges misleading ads

BY Alaric DeArment

WASHINGTON The Food and Drug Administration sent letters to several drug companies Friday accusing them of misleading advertisements for drugs to treat attention-deficit hyperactivity disorder.

The FDA sent the letters to Eli Lilly, Johnson & Johnson, Covidien, Shire and Novartis that overstated the efficacy of the drugs or omitted information about risks. The drugs affected were Shire’s Adderall XR (lisdexamfetamine dimesylate), Lilly’s Strattera (atomoxetine HCl), J&J’s Concerta (methylphenidate HCl), Novartis’ Focalin XR (dexmethylphenidate HCl) and Methylin (methylphenidate), by Covidien subsidiary Mallinckrodt.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Ligand releases details of plan to purchase Pharmacopeia

BY Alaric DeArment

SAN DIEGO Ligand Pharmaceutical plans to buy New Jersey biotech Pharmacopeia for as much as $70 million, the San Diego drug maker has announced.

Ligand’s shareholders will get an 84 percent stake in the new company, while Pharmacopeia shareholders would get a little more than half a share in Ligand for every Pharmacopeia share they own. That makes the deal worth $1.81 per share.

The deal will probably close in the first three months of next year, depending on regulatory and shareholder approvals.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Ontario pharmacies severely underpaid, new study of reimbursements reveals

BY Jim Frederick

TORONTO Retail pharmacies in Ontario are being paid far less for prescriptions dispensed under Canada’s healthcare system than what it costs them to provide those prescriptions to patients, a new study reveals.

In partnership with the Ontario Pharmacists’ Association, the Canadian Association of Chain Drug Stores announced the results of the province-wide study Wednesday at a meeting of the Economic Club of Toronto. Those results, based on an independent survey of 505 community pharmacies across Ontario, show a striking discrepancy between what pharmacies are paid for dispensing medications and what they can recoup for their services.

The independent study found the median cost to provide dispensing and related pharmacy services was $13.77 per prescription. The estimated average payment the provincial government provides to pharmacies for those services, however is far less: approximately $8.70 and declining, according to CACDS president and CEO Nadine Saby, who presented the findings.

“We need to work closely with government to find the innovative and alternative solutions that will ensure the sustainability of patient care and community pharmacy in Canada,” said Saby.

The study was conducted by MENTORx, a consulting firm that specializes in pharmacy-based research. Its aim: to assess the operating costs incurred by Ontario community pharmacies to dispense prescription drugs and deliver related pharmacy services to patients.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?